Prescribing information


Treatment Guidelines

Evidence-based and expert consensus guidelines can offer practical guidance in the diagnosis, monitoring and management of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). This section provides the key European and US clinical practice guidelines, which are relevant for healthcare professionals managing GEP-NETs.

European Neuroendocrine Tumor Society (ENETS): Link to ENETS website

European Society for Medical Oncology (ESMO): Link to ESMO website

North American Neuroendocrine Tumor Society (NANETS): Link to NANETS website

Society of Nuclear Medicine and Molecular Imaging (SNMMI): Link to SNMMI website

National Comprehensive Cancer Network (NCCN): Link to NCCN website

Please note, LUTATHERA® (lutetium [177Lu] oxodotreotide) is approved for use in adults with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs).1 Check the SmPC or prescribing information for licensed indications and administration guidance.


ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Rodney H, Hicks J, Kwekkeboom DJ, Krenning E, et al.
Neuroendocrinology. 2017;105:295–309.

Link to the guidelines

Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Pavel M, Öberg K, Falconi M, et al.
Ann Oncol. 2020;31:844–60.

Link to the guidelines

NANETS/SNMMI Procedure Standard for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Hope TA, Abbott, A, Colucci K, et al.
J Nucl Med. 2019;60:937–43.

Link to the 2019 guidelines

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Hope TA, Bodei L, Chan JA, et al.
J Nucl Med. 2020;61:222–27.

Link to the 2020 guidelines

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Strosberg JA, Halfdanarson TR, Bellizzi AM, et al.
Pancreas. 2017;46:707–14.

Link to the guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Neuroendocrine and Adrenal Tumors. Version 2. 2020 – July 24, 2020.

Shah MH, Goldner WS, Benson AB III, et al. 2020.

Link to the guidelines

1. Lutathera®. Summary of Product Characteristics. Available at: (Accessed October 2023).
AAA-Lu177-UK-2149 | October 2023

Ask Speakers


Medical Information Request